CA2378829A1 — Sustained release drug dispersion delivery device
Assigned to Merck and Co Inc · Expires 2001-01-25 · 25y expired
What this patent protects
The present invention is related to a drug delivery device, that is pH insensitive, for the sustained in situproduction and release of a dispersion, in an environment of use, which comprises a) a compressed core prepared from an admixture comprising i) a therapeutically effective…
USPTO Abstract
The present invention is related to a drug delivery device, that is pH insensitive, for the sustained in situproduction and release of a dispersion, in an environment of use, which comprises a) a compressed core prepared from an admixture comprising i) a therapeutically effective amount of a beneficial agent that has a solubility profile that is dependent on the pH level of the environment of use; ii) a water swellable polymer which upon hydration forms gelatinous microscopic particles; and iii) a pH modulator; a nd b) a water insoluble, water impermeable polymeric coating comprising a polym er and a plasticizer, which surrounds and adheres to the compressed core, said water insoluble, water impermeable polymeric coating having at least one aperture.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.